Can MRI Replace a PET-CT — to Avoid Radiation?

You can and should raise it. Your concern is reasonable, and your oncologist should explain why a particular scan was chosen. In some cases — especially for pelvic or brain cancers — MRI may already be the right scan for you. In others, PET-CT is the only tool that answers the specific clinical question your team needs answered. Understanding why a specific scan was chosen, and whether an alternative exists, is a reasonable expectation at any appointment.

The dose varies by protocol and body size, so we do not publish specific figures here — numbers taken out of context can mislead. What your oncologist can do is put the dose in context: where it sits relative to background radiation or other scans you may already have had. Ask them directly for a comparison that makes sense for your situation. The decision to request the scan reflects a clinical judgement that the information gained outweighs the exposure.

PET-CT is not the standard tool for brain tumours — the brain has naturally high glucose activity that makes the scan harder to read, and MRI gives far better structural detail. It is also not the primary scan for local staging of rectal, cervical or prostate cancer, where MRI maps anatomy more precisely. Your oncologist will specify which modality is appropriate for your particular cancer type and stage, and can explain what they are looking for with each.

Broadly, yes. MRI shows the structure and shape of tissue very well but is less reliable at distinguishing active cancer cells from scar tissue left over from treatment. PET-CT measures metabolic activity — active tumour cells consume more glucose and show up differently from scar tissue. For cancers where this distinction matters, particularly after chemotherapy or radiotherapy, PET-CT and MRI provide genuinely different information. This is one of the main reasons PET-CT cannot always be substituted.

It is being studied as an alternative for surveillance in specific situations, including myeloma and some hereditary cancer syndromes. It is not yet a standard replacement for PET-CT in most solid tumour staging or surveillance, and it is not routinely available at most centres in India. If your cancer type is one where it is being investigated, ask your oncologist whether it is offered at your treating centre and what the current evidence shows for your specific situation.

Both scans require specialist input in pregnancy, and the decision should involve your oncologist and your obstetric team together. PET-CT involves radiation that reaches the foetus, and the radiotracer also passes through breast milk. MRI in pregnancy is used when medically necessary, but contrast agents sometimes used alongside MRI also need careful discussion. Neither decision should be made without specialist input. Tell your team you are pregnant or may be pregnant before any scan is booked — never after.